NCT07633743 MenoZen VR for Menopause Symptom Management
| NCT ID | NCT07633743 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Menopause |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-09-28 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-09-28 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to evaluate the feasibility, acceptability, tolerability, and clinical efficacy of MenoZen VR (virtual reality) for managing menopause symptoms in women.
Eligibility Criteria
Inclusion Criteria: * Women currently between 45-60 years of age; * Have moderate to severe VMS, defined as 28 or more hot flashes per week (including night sweats) and were sufficient severity to prompt them to seek therapeutic intervention; * Are English-speaking; * Able to participate fully in all aspects of the study; * Have understood and signed study informed consent; * Have access to a computer or smartphone and home Wi-Fi; * Willing to participate in weekly VR sessions for 8 weeks. Exclusion Criteria: * Women receiving systemic menopause hormonal therapy (progesterone, testosterone, estrogen). Low-dose topical vaginal estrogen is okay; * Women receiving non-hormonal therapy for the management of hot flashes (fezolinetant or elinzanetant, any SSRI/SNRI, oxybytunin, and/or gabapentin being prescribed for hot flashes, if for other reasons and still with hot flashes then okay); * Women receiving active cognitive behavioral therapy (CBT) for hot flashes. CBT for mood symptoms is okay; * Have a known, active, untreated clinically significant psychiatric condition (severe depression, psychosis, bipolar disorder, or severe depression); * Have severe visual, auditory, or vestibular impairments that may interfere with VR use; * Have a facial/head deformity that will prohibit the wearing of a VR head mounted displace (HMD); * Self-reported history of acute and/or severe motion sickness; * Have had a seizure in the past year; * Concurrently enrolled in another intervention trial for menopause symptoms; * Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.
Contact & Investigator
Chrisandra L. Shufelt, MD, MS
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT07633743 clinical trial?
This trial is open to female participants only, aged 45 Years or older, up to 60 Years, studying Menopause. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07633743 currently recruiting?
Yes, NCT07633743 is actively recruiting participants. Contact the research team at Uy.Lauren@mayo.edu for enrollment information.
Where is the NCT07633743 trial being conducted?
This trial is being conducted at Jacksonville, United States.
Who is sponsoring the NCT07633743 clinical trial?
NCT07633743 is sponsored by Mayo Clinic. The principal investigator is Chrisandra L. Shufelt, MD, MS at Mayo Clinic. The trial plans to enroll 40 participants.